Advancing Medicine,
Improving Lives
Ferro Pharma is a global pharmaceutical leader dedicated to discovering, developing, and delivering breakthrough therapies that transform patients' lives across oncology, cardiology, neurology, and immunology.
Research Highlights
Our scientists are pushing the boundaries of what's possible, tackling diseases that have long resisted treatment.
KRAS Targeting Breakthrough
Our Nexavitol program demonstrated unprecedented tumor regression in KRAS G12C-mutant NSCLC, a historically undruggable target.
Tau Clearance in Alzheimer's
Phase II data shows Neuralyx achieves 78% reduction in CSF tau biomarkers, correlating with slowed cognitive decline.
Bispecific Antibody Platform
Our proprietary CrossLink™ platform enables simultaneous dual-target engagement, opening new frontiers in autoimmune disease.
Approved Medicines
Transformative therapies that are changing the standard of care for patients worldwide.
Cardivex
cardimyosin alfa
Heart Failure (HFrEF)
Cardivex is a first-in-class cardiac myosin activator that directly targets the underlying mechanism of heart failure, improving cardiac output without increasing oxygen demand.
Nexavitol
nexakrasib
KRAS G12C+ Non-Small Cell Lung Cancer
Nexavitol is a covalent KRAS G12C inhibitor that locks the mutant protein in its inactive state, blocking downstream oncogenic signaling in NSCLC.
Immucore-7
immubispecumab
Moderate-to-Severe Rheumatoid Arthritis
Immucore-7 is a bispecific monoclonal antibody that simultaneously neutralizes IL-6 and TNF-α, providing superior disease control in patients who failed prior biologics.
Ready to Make a Difference
in Patients' Lives?
Whether you're a healthcare professional, researcher, investor, or patient advocate, we'd love to connect and explore how we can work together.